Evidence map›Paper›PMID 25006524›Full record

ArticleISRN psychiatry2014

Ziprasidone as adjunctive therapy in severe bipolar patients treated with clozapine.

Natalia Bartolommei, Francesco Casamassima, Laura Pensabene, Federica Luchini, Antonella Benvenuti, Antonello Di Paolo, Luca Cosentino, Mauro Mauri, Lorenzo Lattanzi

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ISRN psychiatry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Natalia BartolommeiDipartimento di Medicina Clinica e Sperimentale, Sezione di Psichiatria, Università di Pisa, Azienda Ospedaliero-Universitaria Pisana, Via Roma, No. 67, 56126 Pisa, Italy.
Francesco CasamassimaDipartimento di Medicina Clinica e Sperimentale, Sezione di Psichiatria, Università di Pisa, Azienda Ospedaliero-Universitaria Pisana, Via Roma, No. 67, 56126 Pisa, Italy.ORCID 0000-0001-6529-962X
Laura PensabeneDipartimento di Medicina Clinica e Sperimentale, Sezione di Psichiatria, Università di Pisa, Azienda Ospedaliero-Universitaria Pisana, Via Roma, No. 67, 56126 Pisa, Italy.
Federica LuchiniDipartimento di Medicina Clinica e Sperimentale, Sezione di Psichiatria, Università di Pisa, Azienda Ospedaliero-Universitaria Pisana, Via Roma, No. 67, 56126 Pisa, Italy.
Antonella BenvenutiDipartimento di Medicina Clinica e Sperimentale, Sezione di Psichiatria, Università di Pisa, Azienda Ospedaliero-Universitaria Pisana, Via Roma, No. 67, 56126 Pisa, Italy.
Antonello Di PaoloDipartimento di Medicina Clinica e Sperimentale, Sezione di Psichiatria, Università di Pisa, Azienda Ospedaliero-Universitaria Pisana, Via Roma, No. 67, 56126 Pisa, Italy.
Luca CosentinoDipartimento di Medicina Clinica e Sperimentale, Sezione di Psichiatria, Università di Pisa, Azienda Ospedaliero-Universitaria Pisana, Via Roma, No. 67, 56126 Pisa, Italy.
Mauro MauriDipartimento di Medicina Clinica e Sperimentale, Sezione di Psichiatria, Università di Pisa, Azienda Ospedaliero-Universitaria Pisana, Via Roma, No. 67, 56126 Pisa, Italy.
Lorenzo LattanziDipartimento di Medicina Clinica e Sperimentale, Sezione di Psichiatria, Università di Pisa, Azienda Ospedaliero-Universitaria Pisana, Via Roma, No. 67, 56126 Pisa, Italy.
University of Pisa · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aim. To confirm the efficacy and tolerability of ziprasidone as adjunctive therapy in bipolar patients partially responding to clozapine or with persisting negative symptoms, overweight, or with metabolic syndrome. Methods. Eight patients with psychotic bipolar disorder were tested with the BPRS, the HAM-D, and the CGI at T0 and retested after 2 weeks (T1). Plasma clozapine and norclozapine levels and BMI were tested at T0 and T1. Results. Ziprasidone was well tolerated by all the patients. BPRS and HAM-D scores were reduced in all patients. BMI was reduced in patients with a BMI at T0 higher than 25. Plasma levels of clozapine and norclozapine showed an irregular course.

Identifiers

PMID25006524
PMCPMC4003829
OpenAlexW2101833287

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.